Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Ozempic Gains First Approval In Canada For Kidney Disease And Cardiovascular Death Risk

Valparaiso,,In,Usa,December,13,,2023:,Ozempic,Pen,And,Box

Health Canada on Tuesday approved Novo Nordisk's (NYSE:NVO) Ozempic (semaglutide) to reduce the risk of kidney disease and cardiovascular deaths in adults with type 2 diabetes.

The approval makes Ozempic the first once-weekly treatment for type 2 diabetes that not only improves glycemic control but also lowers the risk of eGFR decline, end-stage kidney disease, and cardiovascular death.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.